Selection of optimal reference genes for normalization in quantitative RT-PCR
- Inna Chervoneva^{1}Email author,
- Yanyan Li^{2},
- Stephanie Schulz^{1},
- Sean Croker^{1},
- Chantell Wilson^{3},
- Scott A Waldman^{1} and
- Terry Hyslop^{1}
DOI: 10.1186/1471-2105-11-253
© Chervoneva et al; licensee BioMed Central Ltd. 2010
Received: 9 September 2009
Accepted: 14 May 2010
Published: 14 May 2010
Abstract
Background
Normalization in real-time qRT-PCR is necessary to compensate for experimental variation. A popular normalization strategy employs reference gene(s), which may introduce additional variability into normalized expression levels due to innate variation (between tissues, individuals, etc). To minimize this innate variability, multiple reference genes are used. Current methods of selecting reference genes make an assumption of independence in their innate variation. This assumption is not always justified, which may lead to selecting a suboptimal set of reference genes.
Results
We propose a robust approach for selecting optimal subset(s) of reference genes with the smallest variance of the corresponding normalizing factors. The normalizing factor variance estimates are based on the estimated unstructured covariance matrix of all available candidate reference genes, adjusting for all possible correlations. Robustness is achieved through bootstrapping all candidate reference gene data and obtaining the bootstrap upper confidence limits for the variances of the log-transformed normalizing factors. The selection of the reference gene subset is optimized with respect to one of the following criteria: (A) to minimize the variability of the normalizing factor; (B) to minimize the number of reference genes with acceptable upper limit on variability of the normalizing factor, (C) to minimize the average rank of the variance of the normalizing factor. The proposed approach evaluates all gene subsets of various sizes rather than ranking individual reference genes by their stability, as in the previous work. In two publicly available data sets and one new data set, our approach identified subset(s) of reference genes with smaller empirical variance of the normalizing factor than in subsets identified using previously published methods. A small simulation study indicated an advantage of the proposed approach in terms of sensitivity to identify the true optimal reference subset in the presence of even modest, especially negative correlation among the candidate reference genes.
Conclusions
The proposed approach performs comprehensive and robust evaluation of the variability of normalizing factors based on all possible subsets of candidate reference genes. The results of this evaluation provide flexibility to choose from important criteria for selecting the optimal subset(s) of reference genes, unless one subset meets all the criteria. This approach identifies gene subset(s) with smaller variability of normalizing factors than current standard approaches, particularly if there is some nontrivial innate correlation among the candidate genes.
Background
Normalization is important in real-time qRT-PCR analysis because of the need to compensate for intra- and inter-kinetic RT-PCR variations [1–3]. Such variations may be due, for example, to the difference in amount of starting material between the samples, difference in RNA integrity, cDNA sample loading variation, or difference in RT efficiency. One of the most popular methods is normalizing a target gene expression to the ribosomal RNAs (rRNA) or messenger RNAs (mRNA) from an internal control or reference gene(s). Such reference genes, also called housekeeping genes, should be expressed in abundance, not be co-regulated with the target gene, and have minimal innate variability. On the other hand, the expression of these genes should vary in accordance with the experimental error associated with the technique (due to sample processing and loading, etc) in order to correct for these errors through normalization.
The variability of a reference gene has two major sources, experimental variability associated with the technology and the innate or natural variability of the reference gene (between tissues, individuals, etc). The original approach to normalization was to find a single reference gene with the most stable (in the sense of the smallest variability) expression across tissues and individuals. Starting with the work of Vandesompele et al [4], normalization is carried out using a geometric mean (inverse natural logarithm of the mean of the log-transformed gene expressions) of multiple internal control genes as a normalizing factor. The rationale is that the same experimental error should be present in all genes expressed in the same sample, if all genes are processed simultaneously. Thus, the experimental errors of individual replicates are averaged across the reference genes, and a geometric mean provides a more robust estimate of the experimental error than individual reference genes. In cases of unregulated and uncorrelated reference genes, the innate variance component of the geometric mean variance is no larger than the largest innate variance component of individual reference genes divided by their total number. Therefore, by increasing the number of reference genes with bounded innate variance, one can theoretically make the innate variance of their geometric mean as small as desired. However, it is expensive and impractical to process too many reference genes for each sample. Thus, careful selection of a small reference genes subset with optimal properties is very important.
It is well documented that optimal reference genes vary according to tissues and treatments [5–7] and that the final choice of the reference genes should be validated for each particular qRT-PCR study [1, 2, 6]. Thus, as a part of assay validation, candidate reference genes are studied and optimal genes selected for inclusion into normalizing factors.
Vandesompele et al [4] proposed an algorithm that ranks individual candidate reference genes according to their stability measure, which is the average pairwise variation of a particular gene with all other candidate reference genes. The pairwise variation is defined as the standard deviation of the log-transformed ratios of expressions of paired genes. The algorithm first selects a pair of two candidate reference genes that have the highest expression agreement (that is the smallest variability in the ratios) among all possible pairs of genes. Then, the next stable reference gene is identified as the one, which has the highest agreement with the rest of the candidate genes and with the geometric mean of the first two selected reference genes, and so on. Thus, the algorithm relies on sequential pair-wise comparisons, which does not guarantee that the optimal subset of three or more genes would be identified.
A more comprehensive approach to selection of the optimal subset of reference genes is to fit a common model that would allow simultaneous quantification and comparison of variability in all candidate genes. This is the approach taken, for example, in [8–10], where various ANOVA and linear mixed effects models were used for the log-transformed gene expression ratios of all candidate reference genes at once. These models incorporate the average gene effect or the average gene-by-tissue type effect (if multiple tissue types are considered), the effect of each individual sample (within each tissue type) and heteroscedastic error terms with the variances that differ by gene and tissue type. Szabo et al [9] used the variance component estimates from the model to rank the variances of the candidate reference genes and estimate the standard deviation of the log geometric means of the best (in the sense of the smallest variability) gene set for each possible set size (1, 2, 3, and so on). Andersen et al [8] proposed a new measure of gene expression stability based on the variance components estimates from the fitted ANOVA model. Similar to [4], this stability measure also allows ranking individual candidate reference genes from the most to the least stable. Abruzzo et al [10] considered linear mixed effects models for log-transformed gene expression and demonstrated that treating experimental errors as random effects provides a much better model fit than using ANOVA models, whose assumptions were violated.
The crucial assumption underlying all these methods is independence in innate variation of the candidate reference genes. The corresponding statistical models assume that correlation between expressions of different genes in the same sample comes exclusively from the experimental variation in the sample. In contrast, we have observed that even after subtracting the random (or fixed) effects of sample, residuals may exhibit non-trivial correlation between some candidate reference genes (see Results). Therefore, estimates of the standard deviation of the log geometric mean may change substantially when correlation is properly estimated and incorporated. This, in turn, can change the ranking of a subset of candidate reference genes with respect to optimality for inclusion into normalization factors.
We developed a robust approach for directly selecting optimal subset(s) of reference genes rather than addressing stability of individual candidate genes. Our approach is based on estimating the unstructured covariance matrix of all available candidate reference genes and using this covariance matrix to estimate the variances of the log normalizing factors (geometric means of the expression of multiple genes) corresponding to all possible subsets of reference genes. Robustness is achieved through bootstrapping candidate reference gene samples and obtaining the bootstrap upper confidence limits for the variances of the log transformed normalizing factors and average ranks of reference gene subsets with respect to the variance of their geometric mean in all bootstrap samples. A bootstrap procedure was proposed earlier [11] to maximize the robustness of the approach in [4] for ranking individual genes. In contrast, our procedure ranks the entire gene subsets of all possible sizes. Using the proposed approach, the optimal subset of the reference genes may be selected (A) to minimize the variability of the normalizing factor; (B) to minimize the number of reference genes with acceptable upper limit on variability of the normalizing factor; or (C) to minimize the average rank of the variance of the normalizing factor.
Two publicly available data sets and one new data set from the validation study of five candidate reference genes for normalization of guanylyl cyclase C (GUCY2C) mRNA expression in blood are used to illustrate the proposed method and compare to earlier published results. In addition, a small simulation study was conducted to evaluate the performance of the proposed approach under known correlation structures assuming varying degrees of innate correlation among candidate reference genes.
Methods
Model for the log-transformed expression levels of candidate reference genes
To incorporate all correlations among candidate reference genes, we simultaneously model their log-transformed expression levels or threshold cycle (Ct) numbers in a multivariate linear mixed effects model with unstructured covariance matrix. The normality assumption is usually appropriate for log-transformed expression levels or Ct numbers in homogeneous populations of samples.
where vector g = [g_{ 1 },...,g_{ J }] ^{T} and g_{ j }is the average log-transformed expression level for the candidate reference gene j, s_{ i }= [s_{ i },..., s_{ i }] ^{T} is the random effect of i^{th} sample, which reflects the experimental variation and is the same for all genes, so that s_{ i }= s_{ i }[1,...,1] ^{T}, r_{ i }= [r_{ i1 },..., r_{ iJ }] ^{T} is the vector of random gene effects in sample i, and e_{ ik }= [e_{ ik1 },..., e_{ ikJ }] ^{T} is the vector of error terms in replicate k.
where V = σ^{2}1_{J×J} + R + D and 1_{J×J} is J×J matrix of ones.
Our model (1) generalizes models 4 and 5 in [10] by assuming a general unstructured positive definite matrix R rather than imposing a simple uncorrelated structure with R = Diag(δ_{ 1 }^{ 2 },..., δ_{ J }^{ 2 }). Sunberg et al [12] also mention in discussion a model similar to (1) in terms of covariance structure.
where vector g = [g_{ 1 },...,g_{ J }] ^{T} represents now across tissues average log-transformed expression levels for all candidate reference genes j = 1,..., J, and vector g_{t} represents the mean differences in expression attributed to tissue t.
where vectors r_{ i }effectively incorporate both, the random gene effects and the errors of gene expression measures. The multivariate formulation (2) still applies to model (4) with V = σ^{2}1_{J×J} + R. If we consider a specific case of model (4) with s_{i} being fixed rather than random effects (so that V = R) and R = Diag(δ_{ 1 }^{ 2 },..., δ_{ J }^{ 2 }) then we obtain model 1a in [9].
In general, the variance components σ^{2}1_{J×J}, R, and D in models (1) and (4) are not identifiable unless one imposes additional constraints on the structure of R and D. In previous work, R was constrained to be diagonal, which corresponds to the independent random effects of reference genes. Our approach is to estimate V as an unstructured covariance matrix without separating the variance components, and then use V to compute the variance of the log geometric mean of any possible subset of reference genes. An unstructured J×J matrix V has J(J + 1)/2 unknown parameters, with the total of J(J + 1)/2 + J = J(J + 3)/2 unknown parameters for model (2). Hence, one needs at least samples of size N > (J + 3)/2 to estimate model (2). With a moderate number of samples available, the estimates of V may not be reliable. To overcome this, we propose to utilize bootstrap re-sampling and compute the upper confidence bounds for the variances of the geometric means. Such upper confidence bounds would properly reflect uncertainty in estimation of the variances.
Variability of geometric means of multiple genes
Thus, the total variance of the log geometric mean of any subset j_{ 1 }, j_{ 2 },..., j_{ L }of reference genes may be estimated using (6) with the corresponding vector C_{ j1,...,jL }and matrix V, which is estimated by fitting model Y_{ i }~MVN_{ J }(g, V). Representation (6) allows computing the variance of all possible F_{ i }(j_{ 1 },..., j_{ L }) through the nested J cycles exhausting all possibilities for vectors C_{ j1,...,jL }.
Hence, the log geometric mean of any subset of reference genes includes the same variance component σ^{2} corresponding to the experimental error present in all gene expressions for the same sample. Therefore, minimizing the total variability of the log geometric mean is equivalent to minimizing the variability described by R.
Selection of the optimal subset of reference genes
Using model (4) and expression (6), we propose a robust approach for selecting optimal subset(s) of reference genes with the smallest variance of the corresponding normalizing factors. Robustness is achieved through bootstrapping candidate reference genes data to obtain the bootstrap upper confidence limits for the variances of the (log) normalizing factors (geometric means) for all possible gene subsets as well as the distribution of ranks of these variances. The bootstrapping also alleviates the uncertainty in estimation of potentially large number of parameters in unstructured covariance matrix V.
- (i)
Unstructured covariance matrix V of all available candidate reference genes is estimated from model (2). In this work, the estimates of V were computed in SAS PROC MIXED (SAS 9.2, SAS Institute, Cary, NC), but any other software capable of fitting liner mixed effects or MANOVA models may be used as well.
- (ii)
Vectors C_{j1,...,jL} for all possible subsets of reference genes are generated and expression (6) is used to compute the variance of the log geometric mean for each possible subset of reference genes. There is a finite, although rather large number, 2^{J}-1, of possible subsets of J reference genes, and the absolute minimum is always attained. In practical qRT-PCR validation studies, the number of candidate reference genes J would not be expected to be much larger than 10.
- (iii)
All possible subsets of reference genes are ranked from the smallest to the largest variance of the corresponding log geometric mean.
Based on results for all bootstrap samples, we compute the bootstrapped upper 95% confidence limit for the variance of the log geometric mean and the average rank of this variance for all possible subsets of the reference genes. Then the optimal subset of the reference genes may be selected using one of the following criteria:
(A) to minimize the upper 95% confidence limit on variability of the log geometric mean regardless of the number of reference genes required;
(B) to minimize the number of reference genes given that the upper 95% confidence limit on variability is under some acceptable level;
(C) to minimize the average rank of the variance of the log geometric mean.
A simple direct comparison of our method vs. previously proposed methods was performed by computing the log geometric mean and its variance for the optimal subsets (for each set size) selected by different procedures. The advantage is direct evaluation of the log geometric mean of interest while ignoring the rest of the genes, which mimics the prospective use of the selected reference genes (the other candidate reference genes would not be available).
The macros implementing the proposed methodology were developed in SAS 9.2 (SAS Institute, Cary, NC). The corresponding SAS code is included as Additional file 1. Simulation study was also performed using SAS 9.2. The real data were analysed in SAS 9.2 and geNorm 3.5 (VBA applet for Microsoft Excel 2000/XP/2003, version 3.5 http://medgen.ugent.be/~jvdesomp/genorm/).
Results
Data Sets
The first dataset includes relative expression levels of 6 reference genes (ACTB, GAPDH, MRPL19, PSMC4, PUM1, and SF3A1) quantified in 80 breast tumor samples. These data are described in detail in [9] and available for download http://genomebiology.com/content/supplementary/gb-2004-5-8-r59-s1.xls. The second dataset includes expression levels for 10 reference genes ACTB, B2M, GAPDH, HMBS, HPRTI, RPLI3A, SDHA, TBP, UBC, YWHAZ) quantified in 37 neuroblastoma samples. These data (available at the web site http://genomebiology.com/2002/3/7/RESEARCH/0034/additional/) are part of the data from various tissues that were used and described in [4]. This subset was selected because the number of neuroblastoma samples (37) was the highest among all tissue types included in the study reported in [4].
The third dataset comes from a validation study of five candidate reference genes for normalization of guanylyl cyclase C (GUCY2C) mRNA expression in blood. The RT-PCR assay to quantify GUCY2C mRNA in tissues and blood employing external calibration standards of RNA complementary to GUCY2C (cRNA) is described in [13]. This work is a part of the ongoing multi-institutional NCI-funded study of GUCY2C as a biomarker for colorectal cancer [14]. The study will determine the utility of GUCY2C mRNA expression in blood for early detection of recurrence in patients with colorectal cancer. Five candidate reference genes for normalization of GUCY2C expression include ACTB, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), transferrin receptor (TFRC), peptidylprolyl isomerase B (PPIB), and hypoxanthine-guanine phosphoribosyltransferase (HPRT). These genes were previously considered as candidate reference genes for normalizing mRNA expression of various targets in blood. RT-PCR experiments were conducted using an ABI 7900 Sequence Detection System (Applied Biosystems, Foster City, CA). Blood samples from 25 healthy volunteers were analyzed as a part of the validation study of five candidate reference genes. Blood was collected in PaxGene Blood RNA tubes (Qiagen), and RNA was purified according to the manufacturer's instructions.
Here, the log transformed expression levels were computed from the threshold cycle (Ct) numbers as in the MS Excel add-on software gNorm, which implements the method described in [4]. For each candidate reference gene, the largest Ct number is subtracted from the Ct number for each sample, and the difference is exponentiated with the base 2. The resulting expression levels range between 0 and 1, with 1 corresponding to the sample with the smallest threshold cycle number and presumably the largest copy number of the corresponding reference gene.
Results for the breast tumour data
Pearson correlation matrix of the residuals from model (8) fitted to the data from 80 breast tumor samples
ACTB | GAPDH | MRPL | PSMC4 | PUM | ||
---|---|---|---|---|---|---|
GAPDH | Coeff.^{1} | -0.112 | ||||
p-value | 0.324 | |||||
MRPL | Coeff.^{1} | -0.476 | 0.021 | |||
p-value | <.0001 | 0.851 | ||||
PSMC4 | Coeff.^{1} | -0.246 | -0.108 | 0.014 | ||
p-value | 0.028 | 0.340 | 0.903 | |||
PUM | Coeff.^{1} | 0.077 | -0.352 | -0.432 | -0.510 | |
p-value | 0.496 | 0.001 | <.0001 | <.0001 | ||
SF3A1 | Coeff.^{1} | 0.147 | -0.086 | -0.567 | -0.313 | 0.160 |
p-value | 0.194 | 0.447 | <.0001 | 0.005 | 0.156 |
Breast tumor data: Top ranked by set size bootstrap 95% upper confidence limit (UCL) for the variance and standard deviation of the log geometric mean (GM).
Set Size(*) | ACTB | GAPDH | MRPL19 | PSMC4 | PUM | SF3A1 | 95% UCL Var(GM) | 95% UCL StdDev(GM) |
---|---|---|---|---|---|---|---|---|
1 | 1 | 0 | 0 | 0 | 0 | 0 | 0.407 | 0.638 |
2 | 1 | 0 | 0 | 0 | 0 | 1 | 0.349 | 0.591 |
3 | 1 | 0 | 0 | 0 | 1 | 1 | 0.356 | 0.596 |
4 | 1 | 1 | 0 | 0 | 1 | 1 | 0.398 | 0.631 |
5 | 1 | 1 | 0 | 1 | 1 | 1 | 0.429 | 0.655 |
6 | 1 | 1 | 1 | 1 | 1 | 1 | 0.465 | 0.682 |
Breast tumor data: Ten gene subsets with the smallest mean overall ranks of the variance of the log geometric mean (GM).
Set Size(*) | ACTB | GAPDH | MRPL19 | PSMC4 | PUM | SF3A1 | Mean rank of Var(GM) |
---|---|---|---|---|---|---|---|
2 | 1 | 0 | 0 | 0 | 0 | 1 | 1.2 |
3 | 1 | 0 | 0 | 0 | 1 | 1 | 2.0 |
2 | 1 | 0 | 0 | 0 | 1 | 0 | 3.2 |
2 | 0 | 0 | 0 | 0 | 1 | 1 | 4.7 |
4 | 1 | 0 | 0 | 1 | 1 | 1 | 6.1 |
1 | 1 | 0 | 0 | 0 | 0 | 0 | 6.4 |
3 | 1 | 0 | 0 | 1 | 0 | 1 | 8.1 |
1 | 0 | 0 | 0 | 0 | 0 | 1 | 8.8 |
4 | 1 | 0 | 1 | 0 | 1 | 1 | 9.2 |
4 | 1 | 1 | 0 | 0 | 1 | 1 | 10.3 |
3 | 1 | 0 | 1 | 0 | 0 | 1 | 10.6 |
In contrast, using the model in [9], the geometric mean of four genes, MRPL19, PUM1, PSMC4, and SF3A1, has the smallest estimated variability (the innate standard deviation = 0.1490). The geometric mean corresponding to three genes, MRPL19, PUM1, and PSMC4 (the innate standard deviation = 0.1494) yields just a small increase in standard deviation. Thus, MRPL19, PUM1, and PSMC4 may be considered an optimal subset using the approach in [9].
Breast tumor data: Variability of log geometric means based on optimal gene subsets identified by various methods
Set Size | Method | Optimal set | Variance logGM | Std Dev logGM |
---|---|---|---|---|
2 | Szabo et al | MRPL19, PUM1 | 0.517 | 0.719 |
2 | Vandes. et al | MRPL19, PSMC4 | 0.629 | 0.793 |
2 | New | ACTB, SF3A1 | 0.321 | 0.567 |
3 | Szabo et al | MRPL19, PUM1, PSMC4 | 0.531 | 0.729 |
3 | Vandes. et al | MRPL19, PUM1, PSMC4 | 0.531 | 0.729 |
3 | New | ACTB, SF3A1, PUM1 | 0.327 | 0.572 |
4 | Szabo et al ^{1} | MRPL19, PUM1, PSMC4, SF3A1 | 0.464 | 0.681 |
4 | New | ACTB, SF3A1, PUM1, GAPDH | 0.369 | 0.607 |
Results for neuroblastoma data
Neuroblastoma data: Top ranked by set size bootstrap 95% upper confidence limit (UCL) for the variance and standard deviation of the log geometric mean (GM).
Set Size(*) | AC^{1} | B2M | GA^{2} | HM^{3} | HP^{4} | RP^{5} | SD^{6} | TBP | UBC | YW^{7} | 95% UCL Var(GM) | 95% UCL StdDev(GM) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.458 | 0.677 |
2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.340 | 0.583 |
3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.340 | 0.583 |
4 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.303 | 0.550 |
5 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0.299 | 0.547 |
6 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0.298 | 0.546 |
7 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0.303 | 0.550 |
8 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.317 | 0.563 |
9 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.334 | 0.578 |
10 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.353 | 0.594 |
Neuroblastoma data: Ten gene subsets with the smallest mean overall ranks of the variance of the log geometric mean (GM).
Set Size(*) | AC^{1} | B2M | GA^{2} | HM^{3} | HP^{4} | RP^{5} | SD^{6} | TBP | UBC | YW^{7} | Mean rank of Var(GM) |
---|---|---|---|---|---|---|---|---|---|---|---|
6 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 52.1 |
7 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 59.9 |
5 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 63.8 |
6 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 76.7 |
6 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 87.5 |
5 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 92.2 |
6 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 93.3 |
7 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 95.9 |
7 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 96.4 |
7 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 103.0 |
Figure 2 indicates that the set of 7 genes that include all the genes selected using criteria (A) and (C) (ACTB, B2M, GAPDH, HPRT1, RPL13A, TBP, and YWHAZ) may be considered optimal with respect to both criteria (A) (0.005 difference from the minimum upper bound in Table 5) and (C) (second lowest average rank in Table 6). However, the advantage of addressing both criteria may not be worth the increase of the set size from 4 (ACTB, B2M, GAPDH, and TBP) to 7 by adding HPRT1, RPL13A, and YWHAZ. In this situation, criterion (B) with the acceptable upper limit of 0.55 on the standard deviation scale would yield the optimal set ACTB, B2M, GAPDH, and TBP.
Neuroblastoma data: Variability of log geometric means based on optimal gene subsets identified by various methods
Set Size | Method | Optimal set | Variance logGM | Std Dev logGM |
---|---|---|---|---|
2 | Vand | GAPDH, HPRT | 0.327 | 0.572 |
2 | Szabo | GAPDH, SDHA | 0.374 | 0.612 |
2 | New | GAPDH, YWHAZ | 0.250 | 0.500 |
3 | Old^{1} | GAPDH, HPRT, SDHA | 0.348 | 0.590 |
3 | New | ACTB, GAPDH, YWHAZ | 0.255 | 0.505 |
4 | Old^{1} | GAPDH, HPRT, SDHA, UBC | 0.361 | 0.601 |
4 | New | ACTB, B2M, GAPDH, TBP | 0.231 | 0.480 |
5 | Old^{1} | GAPDH, HPRT, SDHA, UBC, HMBS | 0.358 | 0.598 |
5 | New | ACTB, B2M, GAPDH, HPRT1, RPL13A | 0.224 | 0.473 |
6 | Old^{1} | GAPDH, HPRT, SDHA, UBC, HMBS, YWHAZ | 0.319 | 0.565 |
6 | New | ACTB, GAPDH, B2M, HPRT1, TBP, YWHAZ | 0.227 | 0.477 |
Results for five reference genes for GUCY2C in blood
For five candidate reference genes for GUCY2C (ACTB, GAPDH, HPRT, PPIB, and TFRC), the new approach was applied to the log transformed relative expression levels for direct comparison with previously proposed methods and to the threshold cycle (Ct) numbers because Ct numbers are actually used for efficiency adjusted relative quantification [15].
Blood data: Top ranked by set size bootstrap 95% upper confidence limit (UCL) for the variance and standard deviation of the log geometric mean (GM) based on log transformed relative expression levels.
Set Size(*) | ACTB | GAPDH | HPRT1 | PPIB | TFRC | 95% UCL Var(GM) | 95% UCL StdDev(GM) |
---|---|---|---|---|---|---|---|
1 | 0 | 1 | 0 | 0 | 0 | 1.19 | 1.09 |
2 | 0 | 1 | 0 | 0 | 1 | 1.25 | 1.12 |
3 | 0 | 1 | 1 | 0 | 1 | 1.57 | 1.25 |
4 | 0 | 1 | 1 | 1 | 1 | 1.77 | 1.33 |
5 | 1 | 1 | 1 | 1 | 1 | 2.06 | 1.43 |
Blood data: Top ranked by set size bootstrap 95% upper confidence limit (UCL) for the variance and standard deviation of the log geometric mean (GM) based on Ct numbers.
Set Size(*) | ACTB | GAPDH | HPRT1 | PPIB | TFRC | 95% UCL Var(GM) | 95% UCL StdDev(GM) |
---|---|---|---|---|---|---|---|
1 | 0 | 1 | 0 | 0 | 0 | 6.22 | 2.49 |
2 | 0 | 1 | 0 | 0 | 1 | 6.06 | 2.46 |
3 | 0 | 1 | 1 | 0 | 1 | 6.66 | 2.58 |
4 | 1 | 1 | 1 | 0 | 1 | 7.29 | 2.70 |
5 | 1 | 1 | 1 | 1 | 1 | 7.91 | 2.81 |
Blood data: Ten gene subsets with the smallest mean overall ranks of the variance of the log geometric mean (GM) based on log transformed relative expression levels.
Set Size(*) | ACTB | GAPDH | HPRT1 | PPIB | TFRC | Mean rank of Var(GM) |
---|---|---|---|---|---|---|
2 | 0 | 1 | 0 | 0 | 1 | 1.5 |
1 | 0 | 1 | 0 | 0 | 0 | 2.8 |
3 | 0 | 1 | 1 | 0 | 1 | 3.7 |
3 | 1 | 1 | 0 | 0 | 1 | 5.3 |
2 | 0 | 1 | 1 | 0 | 0 | 5.7 |
1 | 0 | 0 | 0 | 0 | 1 | 7.0 |
4 | 1 | 1 | 1 | 0 | 1 | 8.1 |
3 | 0 | 1 | 0 | 1 | 1 | 8.2 |
2 | 1 | 1 | 0 | 0 | 0 | 8.8 |
4 | 0 | 1 | 1 | 1 | 1 | 10.7 |
Blood data: Ten gene subsets with the smallest mean overall ranks of the variance of the log geometric mean (GM) based on Ct numbers.
Set Size(*) | ACTB | GAPDH | HPRT1 | PPIB | TFRC | Mean rank of Var(GM) |
---|---|---|---|---|---|---|
2 | 0 | 1 | 0 | 0 | 1 | 1.7 |
1 | 0 | 1 | 0 | 0 | 0 | 2.1 |
3 | 0 | 1 | 1 | 0 | 1 | 3.5 |
2 | 0 | 1 | 1 | 0 | 0 | 4.4 |
1 | 0 | 0 | 0 | 0 | 1 | 5.3 |
3 | 0 | 1 | 0 | 1 | 1 | 5.6 |
4 | 0 | 1 | 1 | 1 | 1 | 7.3 |
2 | 0 | 1 | 0 | 1 | 0 | 8.3 |
3 | 0 | 1 | 1 | 1 | 0 | 9.6 |
2 | 0 | 0 | 1 | 0 | 1 | 10.4 |
Blood data: Variability of log geometric means based on optimal gene subsets identified by various methods
Set Size | Method | Optimal set | Variance logGM | Std Dev logGM |
---|---|---|---|---|
2 | Szabo et al | TFRC, GAPDH | 0.98 | 0.99 |
2 | Vandes. et al | TFRC, HPRT | 1.47 | 1.21 |
2 | New | TFRC, GAPDH | 0.98 | 0.99 |
3 | Szabo et al | TFRC, GAPDH, PPIB | 1.26 | 1.12 |
3 | Vandes. et al | TFRC, GAPDH, PPIB | 1.62 | 1.27 |
3 | New | TFRC, GAPDH, HPRT | 1.16 | 1.08 |
4 | All methods | GAPDH, PPIBA, TFRC, HPRT | 1.34 | 1.16 |
Simulation study
Design of the simulation study
Min Var of NF^{1} | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scenario | Std Dev | Correlation Matrix of R | Total Covariance Matrix V | No Genes | True | Uncorr ^{ 2 } | ||||||||
0.30 | 1 | 0 | 0 | 0 | 0 | 0.25 | 0.16 | 0.16 | 0.16 | 0.16 | 1 | 0.250 | 0.250 | |
Uncorrelated R | 0.35 | 0 | 1 | 0 | 0 | 0 | 0.16 | 0.28 | 0.16 | 0.16 | 0.16 | 2 | 0.213 | 0.133 |
Sample Random | 0.80 | 0 | 0 | 1 | 0 | 0 | 0.16 | 0.16 | 0.80 | 0.16 | 0.16 | 3 | 0.255 | 0.148 |
Effect Var = 0.16 | 0.90 | 0 | 0 | 0 | 1 | 0 | 0.16 | 0.16 | 0.16 | 0.97 | 0.16 | 4 | 0.264 | 0.144 |
1.00 | 0 | 0 | 0 | 0 | 1 | 0.16 | 0.16 | 0.16 | 0.16 | 1.16 | 5 | 0.267 | 0.139 | |
0.60 | 1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.38 | 0.10 | 0.11 | 0.15 | 0.16 | 1 | 0.380 | 0.380 | |
Corr Coef = 0.2 | 0.70 | 0.2 | 1 | 0.2 | 0.2 | 0.2 | 0.10 | 0.51 | 0.13 | 0.17 | 0.19 | 2 | 0.275 | 0.223 |
Sample Random | 0.75 | 0.2 | 0.2 | 1 | 0.2 | 0.2 | 0.11 | 0.13 | 0.58 | 0.19 | 0.20 | 3 | 0.239 | 0.164 |
Effect Var = 0.02 | 1.10 | 0.2 | 0.2 | 0.2 | 1 | 0.2 | 0.15 | 0.17 | 0.19 | 1.23 | 0.28 | 4 | 0.275 | 0.169 |
1.20 | 0.2 | 0.2 | 0.2 | 0.2 | 1 | 0.16 | 0.19 | 0.20 | 0.28 | 1.46 | 5 | 0.301 | 0.167 | |
0.42 | 1 | -0.2 | -0.2 | 0.2 | 0.2 | 0.28 | 0.06 | 0.06 | 0.15 | 0.15 | 1 | 0.276 | 0.276 | |
Corr Coef = ±0.2 | 0.45 | -0.2 | 1 | -0.2 | 0.2 | 0.2 | 0.06 | 0.30 | 0.06 | 0.15 | 0.15 | 2 | 0.176 | 0.145 |
Sample Random | 0.48 | -0.2 | -0.2 | 1 | 0.2 | 0.2 | 0.06 | 0.06 | 0.33 | 0.16 | 0.16 | 3 | 0.141 | 0.101 |
Effect Var = 0.1 | 0.60 | 0.2 | 0.2 | 0.2 | 1 | 0.2 | 0.15 | 0.15 | 0.16 | 0.46 | 0.17 | 4 | 0.166 | 0.086 |
0.60 | 0.2 | 0.2 | 0.2 | 0.2 | 1 | 0.15 | 0.15 | 0.16 | 0.17 | 0.46 | 5 | 0.175 | 0.073 | |
0.30 | 1 | -0.4 | 0.0 | 0.0 | 0.0 | 0.25 | 0.11 | 0.16 | 0.16 | 0.16 | 1 | 0.250 | 0.090 | |
Corr Coef = ±0.4 | 0.40 | -0.4 | 1 | 0.0 | 0.0 | 0.0 | 0.11 | 0.32 | 0.16 | 0.16 | 0.16 | 2 | 0.199 | 0.063 |
Sample Random | 0.60 | 0.0 | 0.0 | 1 | 0.0 | 0.0 | 0.16 | 0.16 | 0.52 | 0.16 | 0.16 | 3 | 0.217 | 0.068 |
Effect Var = 0.16 | 0.70 | 0.0 | 0.0 | 0.0 | 1 | 0.4 | 0.16 | 0.16 | 0.16 | 0.65 | 0.38 | 4 | 0.223 | 0.069 |
0.80 | 0.0 | 0.0 | 0.0 | 0.4 | 1 | 0.16 | 0.16 | 0.16 | 0.38 | 0.80 | 5 | 0.244 | 0.070 | |
0.40 | 1 | 0.4 | 0.4 | 0.4 | 0.4 | 0.26 | 0.18 | 0.21 | 0.23 | 0.24 | 1 | 0.260 | 0.260 | |
Corr Coef = 0.4 | 0.50 | 0.4 | 1 | 0.4 | 0.4 | 0.4 | 0.18 | 0.35 | 0.24 | 0.26 | 0.28 | 2 | 0.243 | 0.153 |
Sample Random | 0.70 | 0.4 | 0.4 | 1 | 0.4 | 0.4 | 0.21 | 0.24 | 0.59 | 0.32 | 0.35 | 3 | 0.274 | 0.133 |
Effect Var = 0.1 | 0.80 | 0.4 | 0.4 | 0.4 | 1 | 0.4 | 0.23 | 0.26 | 0.32 | 0.74 | 0.39 | 4 | 0.302 | 0.121 |
0.90 | 0.4 | 0.4 | 0.4 | 0.4 | 1 | 0.24 | 0.28 | 0.35 | 0.39 | 0.91 | 5 | 0.331 | 0.114 |
Results of the simulation study
Sensitivity to optimal subset | ||||
---|---|---|---|---|
Scenario | No of samples | UCL ^{ 1 } | Rank ^{ 2 } | Szabo ^{ 3 } |
Uncorrelated R | 25 | 43.00 | 41.75 | 60.25 |
Sample Random | 40 | 53.50 | 53.25 | 73.50 |
Effect Var = 0.16 | 80 | 81.25 | 81.50 | 86.25 |
All Corr Coef = 0.2 | 25 | 34.25 | 36.50 | 38.75 |
Sample Random | 40 | 53.25 | 55.25 | 46.25 |
Effect Var = 0.02 | 80 | 75.75 | 74.50 | 57.25 |
Corr Coef = ±0.2 | 25 | 48.50 | 55.00 | 0.00 |
Sample Random | 40 | 68.00 | 72.75 | 0.25 |
Effect Var = 0.1 | 80 | 91.50 | 93.50 | 0.00 |
Corr Coef = ±0.4 | 25 | 36.50 | 31.50 | 8.50 |
Sample Random | 40 | 49.25 | 42.75 | 7.25 |
Effect Var = 0.16 | 80 | 63.50 | 60.25 | 3.75 |
All Corr Coef = 0.4 | 25 | 37.5 | 40.8 | 23.3 |
Sample Random | 40 | 49.8 | 51.3 | 21.0 |
Effect Var = 0.1 | 80 | 68.0 | 71.5 | 21.3 |
The results of our simulation study suggest that for truly uncorrelated candidate reference genes, the proposed approach may have lower power/sensitivity than the method of Szabo et al [9]. This may be expected since the true V has the structure as assumed in [9], while our approach would estimate unnecessary extra parameters in unstructured V. For equally weakly positively correlated candidate reference genes, performance of our and approach in [9] was similar for smaller sample sizes (25-40), while the new proposed approaches were better for N = 80. When the same weak correlation was assumed positive for some pairs of genes and negative for others, then the proposed approach was clearly superior to the method in [9]. Similarly, our approach performed much better in the scenario with some strongly positively, some strongly negatively, and some uncorrelated pairs of candidate reference genes. Finally, in the case of equally strongly positively correlated candidate reference genes, we also observed an advantage of the proposed approach.
Discussion
In this work, we developed an approach for selecting an optimal set of reference genes for normalization in RT-PCR. The key difference from previously proposed methods is that assumption of independence among candidate reference genes is relaxed, and, instead, the estimated correlation among the genes is incorporated into estimates of variability of the prospective normalizing factors. The proposed approach does not explicitly estimate correlation among the genes, but implicitly the correlation is incorporated into the estimate of the total covariance matrix V. Then the variance of a log transformed prospective normalizing factor is estimated by substituting the estimated V into (6).
To overcome uncertainty in estimating a large number of covariance parameters from usually small data sets, we employ bootstrap to obtain robust upper confidence bounds for the variance of the log geometric means of multiple genes. These bounds allow comparing various gene subsets as prospective normalizing factors, but also may be used in sample size calculations while designing an RT-PCR study. Our approach also allows certain flexibility to choose a criterion for selecting the optimal subset(s) of the reference genes unless one subset meets all the criteria.
Here, our primary focus was on selecting reference genes for normalizing target gene expressions from one tissue as motivated by the study of guanylyl cyclase C (GUCY2C) mRNA expression in blood. Our methodology is easily extendable to multiple tissues or inter-species comparisons by incorporating fixed effects for between-tissue or between-species differences into the mean sub-model Aβ in (3), as long as one can assume that variances and correlation among the genes do not change between tissues or between species. If they do change between tissues or between species, then selecting the same reference genes for different tissues or different species may not be appropriate, or careful consideration may be required to set appropriate criteria of optimal properties of the reference genes that may behave differently in different tissues or species.
In the considered data examples, the use of the proposed methodology yielded generally smaller optimal subsets of the reference genes with smaller variability of the normalizing factors. In direct comparisons, the normalizing factor variances (based on the genes from the selected subset only) were reduced by 27-32% when using the proposed selection approach instead of the methods [4] and [9]. Taken together, the smaller number of reference genes and smaller normalizing factors could result in cost savings due to both reduced primer and probe needs and potentially smaller numbers of samples required for the experiment overall.
Conclusions
The proposed approach performs comprehensive and robust evaluation of the variability of normalizing factors based on all possible subsets of candidate reference genes rather than addressing the stability of individual reference genes. The results of this evaluation provide flexibility to choose more important criterion for selecting the optimal subset(s) of the reference genes unless one subset meets all the criteria. This new approach identifies gene subset(s) with smaller variability of normalizing factors than current standard approaches when there is some nontrivial innate correlation among the candidate genes.
Declarations
Acknowledgements
These studies were supported by NIH grants CA075123, CA79663, CA95026 and CA112147. CW was enrolled in the NIH-supported institutional K30 Training Program in Human Investigation (K30 HL004522) and was supported by NIH institutional award T32 GM08562 for Postdoctoral Training in Clinical Pharmacology. SAW is the Samuel M.V. Hamilton Professor of Medicine of Thomas Jefferson University.
Authors’ Affiliations
References
- Bustin SA: Quantification of Nucleic Acids by PCR. In A-Z of Quantitative PCR. Edited by: Bustin SA. La Jolla: International University Line; 2004:5–46.Google Scholar
- Huggett JF, Dheda K, Bustin SA, Zumla A: Real-time RT-PCR normalisation; strategies and considerations. Genes and Immunity 2005, 6: 1–6. 10.1038/sj.gene.6364190View ArticleGoogle Scholar
- Wong ML, Medrano JF: Real-time PCR for mRNA quantification. BioTechniques 2005, 39: 75–85. 10.2144/05391RV01View ArticlePubMedGoogle Scholar
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002, 3(7):research0034.1–0034.11. 10.1186/gb-2002-3-7-research0034View ArticleGoogle Scholar
- Schmittgen TD, Zakrajsek BA: Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000, 46: 69–81. 10.1016/S0165-022X(00)00129-9View ArticlePubMedGoogle Scholar
- Aerts JL, Gonzales MI, Topalian SL: Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques 2004, 36: 84–86. 88, 90–91 88, 90-91PubMedGoogle Scholar
- Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A: Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004, 37: 112–114. 116, 118–119 116, 118-119PubMedGoogle Scholar
- Andersen CL, Jensen JL, Ørntoft TF: Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets. Cancer Research 2004, 64(15):5245–5250. 10.1158/0008-5472.CAN-04-0496View ArticlePubMedGoogle Scholar
- Szabo A, Perou CM, Karaca M, Perreard L, Quackenbush JF, Bernard PS: Statistical modelling for selecting housekeeper genes. Genome Biology 2004, 5: R59. 10.1186/gb-2004-5-8-r59View ArticlePubMedPubMed CentralGoogle Scholar
- Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, Medeiros LJ, Coombes KR: Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. BioTechniques 2005, 38: 785–792. 10.2144/05385MT01View ArticlePubMedGoogle Scholar
- Gabrielsson BG, Olofsson LE, Sjogren A, Jernas M, Elander A, Lönn M, Rudemo M, Carlsson LMS: Evaluation of reference genes for studies of gene expression in human adipose tissue. Obesity Research 2005, 13: 649–652. 10.1038/oby.2005.72View ArticlePubMedGoogle Scholar
- Sundberg R, Castensson A, Jazin E: Statistical modeling in case-control real-time rt-pcr assays, for identification of differentially expressed genes in schizophrenia. Biostatistics 2006, 7: 130–144. 10.1093/biostatistics/kxi045View ArticlePubMedGoogle Scholar
- Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen C, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA: A validated quantitative assay to detect occult micrometastases by RT-PCR of Guanylyl Cyclase C in patients with colorectal cancer. Clin Cancer Res 2006, 12(15):4545–4552. 10.1158/1078-0432.CCR-06-0865View ArticlePubMedGoogle Scholar
- Carrithers S, Barber MT, Biswas S, Parkinson S, Park P, Goldstein S, Waldman SA: Guanylyl cyclase C is a specific marker for metastatic colorectal tumors in human extraintestinal tissues. Proceedings of the National Academy of Sciences of the United States of America 1996, 93: 14827–14832. 10.1073/pnas.93.25.14827View ArticlePubMedPubMed CentralGoogle Scholar
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 2001, 29: e45. 10.1093/nar/29.9.e45View ArticlePubMedPubMed CentralGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.